Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.310
-0.030 (-2.24%)
At close: Oct 17, 2025, 4:00 PM EDT
1.320
+0.010 (0.76%)
After-hours: Oct 17, 2025, 7:21 PM EDT
Outlook Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Outlook Therapeutics stock have a consensus rating of "Buy" and an average price target of $5.25, which forecasts a 300.76% increase in the stock price over the next year. The lowest target is $1.00 and the highest is $9.00.
Price Target: $5.25 (+300.76%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Outlook Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $1 | Hold | Reiterates | $1 | -23.66% | Sep 30, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $21 → $8 | Strong Buy | Maintains | $21 → $8 | +510.69% | Sep 22, 2025 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $1 | Strong Buy → Hold | Downgrades | $1 | -23.66% | Aug 29, 2025 |
| Chardan Capital | Chardan Capital | Hold Maintains $3 | Hold | Maintains | $3 | +129.01% | Aug 28, 2025 |
Financial Forecast
Revenue This Year
6.85M
Revenue Next Year
28.35M
from 6.85M
Increased by 313.69%
EPS This Year
-1.69
from -4.06
EPS Next Year
-0.99
from -1.69
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 13.2M | 53.5M | ||||
| Avg | 6.9M | 28.4M | ||||
| Low | 4.1M | 15.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 680.7% | ||||
| Avg | - | 313.7% | ||||
| Low | - | 127.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.56 | -0.29 | ||||
| Avg | -1.69 | -0.99 | ||||
| Low | -1.78 | -1.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.